GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

lorigerlimab   Click here for help

GtoPdb Ligand ID: 14407

Synonyms: MGD-019 | MGD019
Immunopharmacology Ligand
Compound class: Antibody
Comment: Lorigerlimab (MGD019) is a tetravalent bispecific IgG4 antibody that simultaneously targets CTLA-4 and PD-1, developed by MacroGenics using DART® technology [1]. It was proposed to reverse the immunosuppressive and immune evasion activities of these two immune checkpoint proteins and thereby enhance the efficacy of tumour-infiltrating lymphocytes in the tumour microenvironment.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
No information available.
Summary of Clinical Use Click here for help
Lorigerlimab (MGD019) was advanced as an oncology clinical lead. In early 2026, the death of a patient from severe side effects (neutropenia and septic shock) in trial NCT06730347 resulted in a halt to enrollment enforced by the FDA.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT06730347 A Study of Lorigerlimab in Participants With Advanced Solid Tumors Phase 2 Interventional MacroGenics
NCT05848011 A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer Phase 2 Interventional MacroGenics
NCT05475171 Triage of Advanced Cervical Cancer Through Immunotherapy Induction (TRACTION) Phase 2 Interventional M.D. Anderson Cancer Center
NCT03761017 MGD019 DART® Protein in Unresectable/Metastatic Cancer Phase 1 Interventional MacroGenics 1